Kiora Pharmaceuticals (KPRX) Competitors $3.99 +0.04 (+1.01%) Closing price 01/30/2025 04:00 PM EasternExtended Trading$3.90 -0.09 (-2.13%) As of 01/30/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KPRX vs. DYAI, ATRA, ESLA, TPST, ITRM, VYNE, RAPT, BRNS, ATNM, and CASIShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Dyadic International (DYAI), Atara Biotherapeutics (ATRA), Estrella Immunopharma (ESLA), Tempest Therapeutics (TPST), Iterum Therapeutics (ITRM), VYNE Therapeutics (VYNE), RAPT Therapeutics (RAPT), Barinthus Biotherapeutics (BRNS), Actinium Pharmaceuticals (ATNM), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Dyadic International Atara Biotherapeutics Estrella Immunopharma Tempest Therapeutics Iterum Therapeutics VYNE Therapeutics RAPT Therapeutics Barinthus Biotherapeutics Actinium Pharmaceuticals CASI Pharmaceuticals Kiora Pharmaceuticals (NASDAQ:KPRX) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Does the MarketBeat Community favor KPRX or DYAI? Dyadic International received 144 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 73.91% of users gave Kiora Pharmaceuticals an outperform vote while only 64.40% of users gave Dyadic International an outperform vote. CompanyUnderperformOutperformKiora PharmaceuticalsOutperform Votes1773.91% Underperform Votes626.09% Dyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% Do analysts rate KPRX or DYAI? Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 150.63%. Dyadic International has a consensus target price of $6.00, indicating a potential upside of 302.68%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KPRX or DYAI more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to Dyadic International's net margin of -188.09%. Kiora Pharmaceuticals' return on equity of 21.32% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A 21.32% 16.39% Dyadic International -188.09%-149.16%-59.81% Do insiders & institutionals believe in KPRX or DYAI? 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 0.9% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 28.8% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer KPRX or DYAI? In the previous week, Dyadic International had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.87 beat Dyadic International's score of 0.77 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Kiora Pharmaceuticals Very Positive Dyadic International Positive Which has higher earnings and valuation, KPRX or DYAI? Dyadic International has higher revenue and earnings than Kiora Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora PharmaceuticalsN/AN/A-$12.51MN/AN/ADyadic International$2.90M15.20-$6.80M-$0.23-6.48 Which has more volatility and risk, KPRX or DYAI? Kiora Pharmaceuticals has a beta of -0.5, meaning that its share price is 150% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. SummaryKiora Pharmaceuticals beats Dyadic International on 8 of the 15 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.97M$6.92B$5.61B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.1189.6917.66Price / SalesN/A351.361,217.4681.09Price / CashN/A65.4844.3437.71Price / Book0.565.335.134.73Net Income-$12.51M$157.56M$118.85M$225.42M7 Day Performance4.18%2.05%1.40%0.75%1 Month Performance20.91%2.62%7.53%3.61%1 Year Performance-19.74%9.59%26.68%21.42% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.9507 of 5 stars$3.99+1.0%$10.00+150.6%-24.7%$11.97MN/A0.0010DYAIDyadic International3.1261 of 5 stars$1.49+1.4%$6.00+302.7%+13.7%$44.09M$2.90M-6.487Short Interest ↓Gap UpATRAAtara Biotherapeutics4.5449 of 5 stars$7.37-10.3%$17.75+140.8%-45.2%$42.45M$8.57M-0.29330Analyst ForecastAnalyst RevisionESLAEstrella Immunopharma0.4955 of 5 stars$1.15+2.1%N/A-0.9%$41.75MN/A-4.44N/AShort Interest ↓Gap DownTPSTTempest Therapeutics2.4141 of 5 stars$0.94-1.1%$20.00+2,027.7%-74.5%$41.02MN/A-0.6120Short Interest ↓ITRMIterum Therapeutics2.1885 of 5 stars$1.49-2.0%$5.00+235.6%-0.6%$41.01MN/A-0.7510Short Interest ↓Positive NewsVYNEVYNE Therapeutics3.1875 of 5 stars$2.75-0.4%$6.88+150.0%+31.8%$40.56M$420,000.00-3.2030Short Interest ↑RAPTRAPT Therapeutics4.7626 of 5 stars$1.16-1.7%$9.56+723.8%-95.5%$40.55M$1.53M-0.4280Short Interest ↓Gap UpBRNSBarinthus Biotherapeutics2.7211 of 5 stars$1.00-0.9%$5.17+416.2%-63.1%$40.27M$14.97M-0.67107Short Interest ↑High Trading VolumeATNMActinium Pharmaceuticals1.6096 of 5 stars$1.29flat$7.40+473.6%N/A$40.25M$80,000.00-0.9330CASICASI Pharmaceuticals4.5459 of 5 stars$2.55-4.1%$6.00+135.3%-62.2%$39.50M$33.88M-1.14180Analyst ForecastShort Interest ↓Positive NewsGap Down Related Companies and Tools Related Companies Dyadic International Competitors Atara Biotherapeutics Competitors Estrella Immunopharma Competitors Tempest Therapeutics Competitors Iterum Therapeutics Competitors VYNE Therapeutics Competitors RAPT Therapeutics Competitors Barinthus Biotherapeutics Competitors Actinium Pharmaceuticals Competitors CASI Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPRX) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
